Insight Molecular Diagnostics shares fall 15.21% intraday after high sales ratio and sector divergence.

Insight Molecular Diagnostics Inc. plunged 15.21% intraday, as the company's stock price-to-sales ratio reached 31.6 times, significantly higher than the industry average of 7.5 times and the European biotech industry average of 8.1 times. Additionally, on June 20, 2025, during premarket trading, the biotech sector saw multiple stocks rise while Insight Molecular's stock price fell 12%, indicating a divergence in funding within the sector.